IL171726A - Quinoline history, use of them @ for the manufacture @ drug @ for relief @ or @ treatment of a clinical condition in which there is an indication of selective pde4 inhibitor, their preparation and pharmaceutical compositions containing them - Google Patents

Quinoline history, use of them @ for the manufacture @ drug @ for relief @ or @ treatment of a clinical condition in which there is an indication of selective pde4 inhibitor, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL171726A
IL171726A IL171726A IL17172605A IL171726A IL 171726 A IL171726 A IL 171726A IL 171726 A IL171726 A IL 171726A IL 17172605 A IL17172605 A IL 17172605A IL 171726 A IL171726 A IL 171726A
Authority
IL
Israel
Prior art keywords
prophylaxis
medicaments
manufacture
indicated
preparation
Prior art date
Application number
IL171726A
Other languages
English (en)
Hebrew (he)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311688A external-priority patent/GB0311688D0/en
Priority claimed from GB0326187A external-priority patent/GB0326187D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL171726A publication Critical patent/IL171726A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL171726A 2003-05-21 2005-11-02 Quinoline history, use of them @ for the manufacture @ drug @ for relief @ or @ treatment of a clinical condition in which there is an indication of selective pde4 inhibitor, their preparation and pharmaceutical compositions containing them IL171726A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0311688A GB0311688D0 (en) 2003-05-21 2003-05-21 Compounds
GB0326187A GB0326187D0 (en) 2003-11-10 2003-11-10 Compounds
PCT/EP2004/005494 WO2004103998A1 (en) 2003-05-21 2004-05-19 Quinoline derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
IL171726A true IL171726A (en) 2013-07-31

Family

ID=33477765

Family Applications (1)

Application Number Title Priority Date Filing Date
IL171726A IL171726A (en) 2003-05-21 2005-11-02 Quinoline history, use of them @ for the manufacture @ drug @ for relief @ or @ treatment of a clinical condition in which there is an indication of selective pde4 inhibitor, their preparation and pharmaceutical compositions containing them

Country Status (30)

Country Link
US (4) US7566786B2 (https=)
EP (2) EP1944305B1 (https=)
JP (1) JP4625460B2 (https=)
KR (1) KR101144548B1 (https=)
CN (1) CN1823063B (https=)
AR (1) AR044401A1 (https=)
AT (2) ATE529421T1 (https=)
AU (1) AU2004240759B2 (https=)
BR (1) BRPI0410477A (https=)
CA (1) CA2526228C (https=)
CO (1) CO5700780A2 (https=)
CY (2) CY1108094T1 (https=)
DE (1) DE602004012260T2 (https=)
DK (2) DK1633748T3 (https=)
EG (1) EG24774A (https=)
ES (2) ES2374850T3 (https=)
HR (2) HRP20080236T3 (https=)
IL (1) IL171726A (https=)
IS (1) IS2581B (https=)
MA (1) MA27808A1 (https=)
MX (1) MXPA05012466A (https=)
NO (1) NO330754B1 (https=)
NZ (1) NZ543554A (https=)
PL (2) PL1944305T3 (https=)
PT (2) PT1633748E (https=)
RU (1) RU2335493C2 (https=)
SI (2) SI1944305T1 (https=)
TW (1) TWI328009B (https=)
WO (1) WO2004103998A1 (https=)
ZA (1) ZA200509319B (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0425572D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
GB0503955D0 (en) * 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
GB0505621D0 (en) * 2005-03-18 2005-04-27 Glaxo Group Ltd Novel compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
BRPI0615948A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc composto ativo de ppar, sua composição, seu kit e seu uso
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0708337A2 (pt) 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
WO2007103554A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
GB0605462D0 (en) * 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
WO2007125952A1 (ja) * 2006-04-28 2007-11-08 Shionogi & Co., Ltd. Ｎｐｙ ｙ５受容体拮抗作用を有するアミン誘導体
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
CN102239149B (zh) 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
JP2012513464A (ja) * 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
CA2796826A1 (en) * 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
US9156791B2 (en) 2010-10-21 2015-10-13 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20130225524A1 (en) * 2010-11-05 2013-08-29 Deping Chai Chemical Compounds
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
US9604963B2 (en) * 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
IN2014CN03234A (https=) * 2011-11-03 2015-07-03 Merck Sharp & Dohme
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
WO2014120995A2 (en) 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
CA2902132C (en) 2013-02-21 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
RU2016112268A (ru) 2013-10-17 2017-11-22 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
AU2016236669B2 (en) * 2015-03-24 2018-11-08 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
EP3558319A4 (en) * 2016-12-22 2020-07-22 AbbVie Inc. COMPOSITIONS AND PROCESSES FOR IMPROVING OR INCREASING THE PRODUCTION OF TYPE I IFN
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
CN120457119A (zh) * 2023-01-17 2025-08-08 瑞石生物医药有限公司 Pde4抑制剂、其制备方法及其在医药上的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE46886B1 (en) 1977-05-17 1983-10-19 Allen & Hanburys Ltd Aminoalkyl-benzene derivatives
EP0048005A3 (de) * 1980-09-17 1983-01-19 ALFA-Institut für hauswirtschaftliche Produkt- und Verfahrens-Entwicklung GmbH Vorrichtung zum Stapeln von Geschirr
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
JPH04211661A (ja) * 1990-03-28 1992-08-03 Otsuka Pharmaceut Co Ltd キノリン誘導体及び該誘導体を含有する抗潰瘍剤
US5214191A (en) 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
EP0752853B1 (en) 1993-03-10 2005-09-21 Smithkline Beecham Corporation Human brain phosphodiesterase
FR2705346B1 (fr) 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
DE69529101T2 (de) 1994-06-15 2003-11-13 Wellcome Found Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren
AU722662B2 (en) * 1996-05-20 2000-08-10 Darwin Discovery Limited Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
PL341364A1 (en) 1997-12-22 2001-04-09 Upjohn Co 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
IL142092A0 (en) 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
ATE255575T1 (de) 1998-09-29 2003-12-15 Wyeth Corp Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
MY121142A (en) 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
KR20020008127A (ko) 1999-03-15 2002-01-29 스티븐 에프. 웨인스톡 항균 활성을 갖는 6-ｏ-치환된 매크롤라이드
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
EP1324990B1 (en) 2000-09-29 2014-10-29 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
WO2003035621A1 (en) 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
EP1470131A2 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
WO2004000828A1 (en) 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
CA2518398A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
ES2374850T3 (es) 2012-02-22
EP1944305A1 (en) 2008-07-16
WO2004103998A1 (en) 2004-12-02
HK1092458A1 (en) 2007-02-09
CA2526228C (en) 2010-08-03
CY1108094T1 (el) 2014-02-12
JP4625460B2 (ja) 2011-02-02
IS2581B (is) 2010-02-15
RU2005135016A (ru) 2006-06-27
NZ543554A (en) 2008-09-26
JP2007501264A (ja) 2007-01-25
US7572915B2 (en) 2009-08-11
MXPA05012466A (es) 2006-01-30
CN1823063A (zh) 2006-08-23
KR20060015278A (ko) 2006-02-16
EP1944305B1 (en) 2011-10-19
KR101144548B1 (ko) 2012-05-11
PT1633748E (pt) 2008-05-20
RU2335493C2 (ru) 2008-10-10
TW200500358A (en) 2005-01-01
HRP20110957T1 (hr) 2012-01-31
DK1633748T3 (da) 2008-06-30
US7566786B2 (en) 2009-07-28
CN1823063B (zh) 2010-07-14
EG24774A (en) 2010-08-19
DE602004012260T2 (de) 2009-03-12
CY1112232T1 (el) 2015-12-09
PT1944305E (pt) 2012-01-11
NO20055421L (no) 2005-12-20
NO20055421D0 (no) 2005-11-16
BRPI0410477A (pt) 2006-05-30
DK1944305T3 (da) 2012-01-30
ATE388148T1 (de) 2008-03-15
EP1633748A1 (en) 2006-03-15
AU2004240759B2 (en) 2010-03-04
US20060178416A1 (en) 2006-08-10
IS8110A (is) 2005-10-31
ZA200509319B (en) 2007-02-28
ATE529421T1 (de) 2011-11-15
CA2526228A1 (en) 2004-12-02
US20090312325A1 (en) 2009-12-17
DE602004012260D1 (https=) 2008-04-17
SI1633748T1 (sl) 2008-08-31
NO330754B1 (no) 2011-07-04
US20070142373A1 (en) 2007-06-21
CO5700780A2 (es) 2006-11-30
HK1118274A1 (en) 2009-02-06
HRP20080236T3 (en) 2008-06-30
US20070049570A1 (en) 2007-03-01
TWI328009B (en) 2010-08-01
PL1944305T3 (pl) 2012-03-30
AR044401A1 (es) 2005-09-14
SI1944305T1 (sl) 2012-02-29
EP1633748B1 (en) 2008-03-05
PL1633748T3 (pl) 2008-07-31
AU2004240759A1 (en) 2004-12-02
MA27808A1 (fr) 2006-03-01
ES2301993T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
IL171726A (en) Quinoline history, use of them @ for the manufacture @ drug @ for relief @ or @ treatment of a clinical condition in which there is an indication of selective pde4 inhibitor, their preparation and pharmaceutical compositions containing them
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
IL175221A (en) Quinazolinyl derivatives, preparations and drugs containing them and their uses for the preparation of drugs for the treatment of hyperproliferative irregularities and inflammatory conditions
IL174647A (en) Pyrazolopyridines and analogs thereof, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL163691A (en) 5-phenylthiazole derivatives, process for their preparation, compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by pi3 kinase
IL164373A (en) Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer
IL183512A (en) Annals of 5-Amino-2-Oxo-Thiazolo [d-5,4] Pyrimidine-3 (or 2) Ill- Tetrahydroporan, Containing and Using Pharmaceutical Preparations
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
IL179611A (en) History 1-Aza-bicycloalkyl, their process, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of psychotic disorders
IL163894A (en) 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
IL176236A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
IL191486A0 (en) Piperidine derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for the treatment of tachykinis mediated conditions
IL170120A (en) 4,2,1 - Triazines, their use in the preparation of HIV treatment or prophylaxis drugs, containing pharmaceutical preparations and methods for their preparation
IL171683A (en) Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
HUP0303296A3 (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
IL177283A (en) Pyrazolopyrimidine compounds, their use in the preparation of medicines and pharmaceuticals containing them
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
IL164845A (en) 2-(alpha-hydroxypentyl)benzoate, its preparation, pharmaceutical compositions comprising it and their use in the preparation of medicaments
IL175568A (en) Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases
IL209879A0 (en) Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees